ZA99607B - Substituted oxoazaheterocyclyl factor xa inhibitors. - Google Patents
Substituted oxoazaheterocyclyl factor xa inhibitors.Info
- Publication number
- ZA99607B ZA99607B ZA9900607A ZA99607A ZA99607B ZA 99607 B ZA99607 B ZA 99607B ZA 9900607 A ZA9900607 A ZA 9900607A ZA 99607 A ZA99607 A ZA 99607A ZA 99607 B ZA99607 B ZA 99607B
- Authority
- ZA
- South Africa
- Prior art keywords
- inhibitors
- factor
- substituted
- substituted oxoazaheterocyclyl
- oxoazaheterocyclyl factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7270798P | 1998-01-27 | 1998-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA99607B true ZA99607B (en) | 1999-07-27 |
Family
ID=22109280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9900607A ZA99607B (en) | 1998-01-27 | 1999-01-27 | Substituted oxoazaheterocyclyl factor xa inhibitors. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7612075B2 (xx) |
| EP (1) | EP1051176B1 (xx) |
| JP (1) | JP4676613B2 (xx) |
| KR (1) | KR20010034442A (xx) |
| CN (1) | CN1291892A (xx) |
| AP (1) | AP2000001889A0 (xx) |
| AT (1) | ATE346050T1 (xx) |
| AU (1) | AU745425B2 (xx) |
| BG (1) | BG104633A (xx) |
| BR (1) | BR9907300A (xx) |
| CA (1) | CA2319198C (xx) |
| DE (1) | DE69934093T2 (xx) |
| EA (1) | EA200000768A1 (xx) |
| EE (1) | EE200000435A (xx) |
| HU (1) | HUP0101810A3 (xx) |
| IL (2) | IL137517A0 (xx) |
| IS (1) | IS5574A (xx) |
| NO (1) | NO20003808L (xx) |
| PL (1) | PL342243A1 (xx) |
| SK (1) | SK11082000A3 (xx) |
| TR (1) | TR200002182T2 (xx) |
| UA (1) | UA59433C2 (xx) |
| WO (1) | WO1999037304A1 (xx) |
| YU (1) | YU47600A (xx) |
| ZA (1) | ZA99607B (xx) |
Families Citing this family (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6525042B1 (en) * | 1997-09-30 | 2003-02-25 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
| CN1290254A (zh) * | 1998-02-05 | 2001-04-04 | 武田药品工业株式会社 | 氨磺酰衍生物及其制备和用途 |
| US7517884B2 (en) | 1998-03-30 | 2009-04-14 | Kalypsys Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
| US6747023B1 (en) * | 1998-08-11 | 2004-06-08 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
| WO2000032590A1 (en) * | 1998-11-25 | 2000-06-08 | Aventis Pharmaceuticals Products Inc. | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS |
| WO2000039102A1 (en) * | 1998-12-23 | 2000-07-06 | Du Pont Pharmaceuticals Company | THROMBIN OR FACTOR Xa INHIBITORS |
| EP1188755B1 (en) | 1999-06-22 | 2006-05-03 | Takeda Pharmaceutical Company Limited | Acylhydrazine derivatives, process for preparing the same and use thereof |
| PL354998A1 (en) * | 1999-07-28 | 2004-03-22 | Aventis Pharmaceuticals Products Inc. | Substituted oxoazaheterocyclyl compounds |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| JP2001294572A (ja) * | 2000-02-09 | 2001-10-23 | Dai Ichi Seiyaku Co Ltd | 新規スルホニル誘導体 |
| DE10012732A1 (de) | 2000-03-18 | 2001-09-20 | Aventis Behring Gmbh | Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung |
| AR030357A1 (es) | 2000-08-18 | 2003-08-20 | Lundbeck & Co As H | Derivados 4 -, 5 -, 6 - y 7-indol |
| CA2422873A1 (en) * | 2000-09-29 | 2002-04-04 | Wenhao Li | Piperazin-2-one amides as inhibitors of factor xa |
| AU2002214266A1 (en) | 2000-11-08 | 2002-05-21 | Takeda Chemical Industries Ltd. | Carbamate derivatives, process for producing the same and use thereof |
| DE10105989A1 (de) | 2001-02-09 | 2002-08-14 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
| HUP0401109A3 (en) | 2001-04-18 | 2007-12-28 | Euro Celtique Sa | Nociceptin analogs, their use and pharmaceutical compositions containing them |
| GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| GB0114005D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| GB0114004D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| DE10129725A1 (de) | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
| NZ530202A (en) | 2001-07-02 | 2005-06-24 | Astrazeneca Ab | Piperidine derivatives useful as modulators of chemokine receptor activity |
| DE10134482A1 (de) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte Isoindole und ihre Verwendung |
| DE10137163A1 (de) | 2001-07-30 | 2003-02-13 | Bayer Ag | Substituierte Isoindole und ihre Verwendung |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| AU2002332640B2 (en) | 2001-08-24 | 2007-11-08 | University Of South Florida | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| DE10155727A1 (de) * | 2001-11-13 | 2003-05-28 | Morphochem Ag | Serin Protease Inhibitoren |
| SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| GB0130677D0 (en) | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| JP4583760B2 (ja) | 2002-02-01 | 2010-11-17 | ユーロ−セルティーク エス．エイ． | 疼痛の治療に有用な治療薬 |
| EP1472222A1 (en) | 2002-02-08 | 2004-11-03 | Glaxo Group Limited | Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases |
| GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| CN1659161A (zh) | 2002-04-16 | 2005-08-24 | 帝人株式会社 | 具有ccr3拮抗作用的哌啶衍生物 |
| US7524841B2 (en) | 2002-04-25 | 2009-04-28 | Teijin Limited | 4,4-disubstituted piperidine derivatives having CCR3 antagonism |
| KR20030084444A (ko) * | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
| US6864261B2 (en) | 2002-05-02 | 2005-03-08 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| AR040336A1 (es) | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto |
| AU2003302238A1 (en) | 2002-12-03 | 2004-06-23 | Axys Pharmaceuticals, Inc. | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors |
| US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
| US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| GB0314738D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| PT1641775E (pt) | 2003-07-03 | 2009-04-23 | Euro Celtique Sa | Derivados de 2-piridina-alcino úteis para o tratamento da dor |
| KR100954415B1 (ko) | 2003-07-24 | 2010-04-26 | 유로-셀띠끄 소시에떼 아노님 | 피페리딘 화합물 및 그들을 포함하는 약학적 조성물 |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| WO2005049559A2 (en) | 2003-11-17 | 2005-06-02 | Boehringer Ingelheim International Gmbh | Novel piperidine-substituted indoles- or hetero-derivatives thereof and their use as modulators of chemokine receptor (ccr-3) |
| DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| EP1722792A1 (de) * | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| US7269708B2 (en) * | 2004-04-20 | 2007-09-11 | Rambus Inc. | Memory controller for non-homogenous memory system |
| GB0414093D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| KR100946219B1 (ko) * | 2004-09-03 | 2010-03-08 | 주식회사유한양행 | 피롤로[3,2-ｃ]피리딘 유도체 및 그의 제조방법 |
| GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| RU2384576C2 (ru) | 2004-10-29 | 2010-03-20 | Калипсис, Инк | Сульфонил-замещенные бициклические соединения в качестве модуляторов ppar |
| EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
| BRPI0608205B8 (pt) | 2005-02-17 | 2021-05-25 | Astellas Pharma Inc | derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado, composição farmacêutica e uso do dito composto para o tratamento de frequência urinária, incontinência urinária, bexiga hiperativa e dor |
| US8197472B2 (en) | 2005-03-25 | 2012-06-12 | Maquet Cardiovascular, Llc | Tissue welding and cutting apparatus and method |
| US7918848B2 (en) | 2005-03-25 | 2011-04-05 | Maquet Cardiovascular, Llc | Tissue welding and cutting apparatus and method |
| ATE531706T1 (de) | 2005-04-30 | 2011-11-15 | Boehringer Ingelheim Int | Neue piperidin-substituierte indole und ihre verwendung als ccr-3-modulatoren |
| US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| WO2007011293A1 (en) | 2005-07-21 | 2007-01-25 | Astrazeneca Ab | Novel piperidine derivatives |
| US7544685B2 (en) | 2005-08-17 | 2009-06-09 | H. Lundbeck A/S | 2,3-dihydroindole compounds |
| JP5147401B2 (ja) * | 2005-09-06 | 2013-02-20 | 塩野義製薬株式会社 | Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体 |
| DE102005045518A1 (de) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
| EP2407459A1 (en) | 2005-09-27 | 2012-01-18 | Shionogi & Co., Ltd. | Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity |
| DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
| BRPI0616801B8 (pt) | 2005-10-04 | 2021-05-25 | Bayer Healthcare Ag | "forma polimórfica de 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofenocarboxamida, seus processos de preparação e seus usos, medicamento, e processo para prevenção de coagulação de sangue in vitro |
| EP1940815B1 (en) | 2005-10-25 | 2018-08-15 | Kalypsys, Inc. | Salts of modulators of ppar and methods of treating metabolic disorders |
| WO2007080430A1 (en) * | 2006-01-16 | 2007-07-19 | Generics [Uk] Limited | Novel process |
| US8247442B2 (en) * | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
| WO2007118853A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| WO2007118854A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
| US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| US7671062B2 (en) | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
| US7629351B2 (en) | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
| US7687508B2 (en) | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| JP2010505811A (ja) * | 2006-10-04 | 2010-02-25 | ファイザー・プロダクツ・インク | カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体 |
| EP2079725B1 (en) | 2006-10-27 | 2011-12-14 | Boehringer Ingelheim International GmbH | Piperidyl-propane-thiol ccr3 modulators |
| US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| SI2069324T1 (sl) * | 2007-03-20 | 2013-10-30 | Curis, Inc. | Kondenzirani aminopiridini kot HSP90-inhibitorji |
| US8173645B2 (en) * | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| CA2833209C (en) | 2007-04-27 | 2016-06-28 | Purdue Pharma L.P. | Piperidine and piperazine compounds as trpv1 antagonists |
| CA2685121A1 (en) | 2007-04-27 | 2008-11-06 | Purdue Pharma L.P. | Therapeutic agents useful for treating pain |
| AU2008277796A1 (en) * | 2007-07-19 | 2009-01-22 | F. Hoffmann-La Roche Ag | Novel heterocyclyl compounds and their use as chemokine antagonists |
| WO2009024823A2 (en) | 2007-08-22 | 2009-02-26 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
| WO2009040659A2 (en) * | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| AR068764A1 (es) * | 2007-10-10 | 2009-12-02 | Takeda Pharmaceutical | N-piperazin amidas y su uso en medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de faah. |
| EP2212300A1 (en) | 2007-10-26 | 2010-08-04 | Glaxo Group Limited | 4-benz0yl-1-substituted-piperazin-2-0ne derivatives as p2x7 modulators |
| KR100967171B1 (ko) | 2007-12-26 | 2010-07-05 | 재단법인서울대학교산학협력재단 | Δ5-2-옥소피페라진 유도체 및 그의 고체상 합성 방법 |
| ES2718813T3 (es) | 2008-03-12 | 2019-07-04 | Ube Industries | Compuesto de ácido piridilaminoacético |
| TW200944526A (en) | 2008-04-22 | 2009-11-01 | Vitae Pharmaceuticals Inc | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| US9402679B2 (en) | 2008-05-27 | 2016-08-02 | Maquet Cardiovascular Llc | Surgical instrument and method |
| US9968396B2 (en) | 2008-05-27 | 2018-05-15 | Maquet Cardiovascular Llc | Surgical instrument and method |
| US9402680B2 (en) | 2008-05-27 | 2016-08-02 | Maquet Cardiovasular, Llc | Surgical instrument and method |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
| US8703962B2 (en) * | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
| CN104163816A (zh) | 2008-12-03 | 2014-11-26 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
| CN102264701A (zh) | 2008-12-23 | 2011-11-30 | 霍夫曼-拉罗奇有限公司 | 作为p2x7调节剂的二氢吡啶酮脲 |
| CA2747925A1 (en) | 2008-12-23 | 2010-07-01 | F. Hoffmann-La Roche Ag | Dihydropyridone amides as p2x7 modulators |
| SG172385A1 (en) | 2008-12-23 | 2011-08-29 | Hoffmann La Roche | Dihydropyridone amides as p2x7 modulators |
| CN102264723B (zh) | 2008-12-23 | 2014-12-10 | 霍夫曼-拉罗奇有限公司 | 作为p2x7调节剂的二氢吡啶酮酰胺 |
| US8153808B2 (en) | 2008-12-23 | 2012-04-10 | Roche Palo Alto Llc | Dihydropyridone amides as P2X7 modulators |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| ES2564010T3 (es) | 2009-03-30 | 2016-03-17 | Ube Industries, Ltd. | Composición farmacéutica para tratar o prevenir el glaucoma |
| TW201044234A (en) * | 2009-06-08 | 2010-12-16 | Chunghwa Picture Tubes Ltd | Method of scanning touch panel |
| US9955858B2 (en) | 2009-08-21 | 2018-05-01 | Maquet Cardiovascular Llc | Surgical instrument and method for use |
| US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| WO2011050284A1 (en) * | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Pyrazolylpyridine antiviral agents |
| JP2013509391A (ja) | 2009-10-30 | 2013-03-14 | グラクソ グループ リミテッド | （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態 |
| TWI494301B (zh) | 2010-02-18 | 2015-08-01 | Astrazeneca Ab | 製備環丙基醯胺衍生物之方法及相關中間物 |
| EP2585446A4 (en) | 2010-06-22 | 2013-12-25 | Shionogi & Co | COMPOUNDS WITH ANTAGONISTIC EFFECT AGAINST TRPV1 AND THEIR USE |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| CN103261205B (zh) * | 2010-11-12 | 2015-08-19 | 姚雪彪 | 动点马达蛋白cenp-e小分子抑制剂syntelin及其应用 |
| WO2012071369A2 (en) | 2010-11-24 | 2012-05-31 | The Trustees Of Columbia University In The City Of New York | A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease |
| EP2723732B1 (en) | 2011-06-22 | 2017-01-18 | Purdue Pharma LP | Trpv1 antagonists including dihydroxy substituent and uses thereof |
| WO2013021276A1 (en) | 2011-08-10 | 2013-02-14 | Purdue Pharma L.P. | Trpv1 antagonists including dihydroxy substituent and uses thereof |
| US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
| WO2014151936A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles, their preparation and use |
| EP3495357B1 (en) | 2013-03-14 | 2021-05-05 | The Trustees of Columbia University in the City of New York | 4-phenylpiperidines, their preparation and use |
| US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
| ES2700541T3 (es) | 2013-03-14 | 2019-02-18 | Univ Columbia | Octahidrociclopentapirroles, su preparación y uso |
| EP2824806B1 (en) * | 2013-07-09 | 2020-03-04 | ABB Schweiz AG | Ship's propulsion unit |
| AU2015253232B2 (en) | 2014-04-30 | 2020-10-01 | The Trustees Of Columbia University In The City Of New York | Substituted 4-phenylpiperidines, their preparation and use |
| PE20180500A1 (es) | 2015-06-26 | 2018-03-09 | Takeda Pharmaceuticals Co | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1 |
| WO2017012502A1 (en) | 2015-07-17 | 2017-01-26 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| WO2017069173A1 (ja) | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2017076900A1 (en) | 2015-11-02 | 2017-05-11 | Janssen Pharmaceutica Nv | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND |
| CN109937202B (zh) | 2016-11-02 | 2022-12-30 | 詹森药业有限公司 | 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物 |
| AU2017353313C1 (en) | 2016-11-02 | 2022-06-09 | Janssen Pharmaceutica Nv | (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors |
| CA3041412A1 (en) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
| WO2018194181A1 (en) | 2017-04-18 | 2018-10-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds useful as modulators of acetylcholine receptors |
| CN116606271B (zh) * | 2023-07-21 | 2023-09-29 | 北京百力格生物科技有限公司 | 一种3,6-二氯偏苯三酸酐的合成方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2877227A (en) * | 1959-03-10 | Chichi | ||
| GB808046A (en) * | 1955-12-13 | 1959-01-28 | Roche Products Ltd | Novel substituted pyridone-acetic acid derivatives and process for the manufacture thereof |
| US3935214A (en) * | 1968-07-26 | 1976-01-27 | Donau-Pharmazie Gesellschaft M.B.H. | 2-or 3 keto-3-or-2-phenyl-1,4-disubstituted piperazines |
| JPS49110680A (xx) * | 1973-03-12 | 1974-10-22 | ||
| JPS5793962A (en) * | 1980-12-01 | 1982-06-11 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| IL92011A0 (en) * | 1988-10-19 | 1990-07-12 | Abbott Lab | Heterocyclic peptide renin inhibitors |
| US5120718A (en) * | 1991-06-13 | 1992-06-09 | Abbott Laboratories | Candida acid protease inhibiting compounds |
| TW394760B (en) * | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
| IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| EP0805149A4 (en) | 1994-12-01 | 1998-03-11 | Toyama Chemical Co Ltd | NEW 2,3-DICETOPIPERAZINE DERIVATIVE OR SALT THEREOF |
| GB9508622D0 (en) | 1995-04-28 | 1995-06-14 | Pfizer Ltd | Therapeutic agants |
| US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
| GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
| GB9602166D0 (en) | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| GB9602294D0 (en) | 1996-02-05 | 1996-04-03 | Zeneca Ltd | Heterocyclic compounds |
| WO1997036605A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JP2002503207A (ja) * | 1996-04-17 | 2002-01-29 | デュポン ファーマシューティカルズ カンパニー | Ｘａ因子阻害剤としてのＮ―（アミジノフェニル）―Ｎ’―（置換）―３Ｈ―２，４―ベンゾジアゼピン―３―オン誘導体 |
| PL331599A1 (en) | 1996-08-14 | 1999-08-02 | Zeneca Ltd | Substituted derivatives of pyrimidine and their pharmaceutical application |
| AU4172397A (en) * | 1996-09-06 | 1998-03-26 | Biochem Pharma Inc. | Lactam inhibitors of thrombin |
| UA56197C2 (uk) * | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Гетероциклічні похідні |
| AU747531B2 (en) * | 1997-04-14 | 2002-05-16 | Millennium Pharmaceuticals, Inc. | Selective factor Xa inhibitors |
| JP2001523226A (ja) * | 1997-04-14 | 2001-11-20 | シーオーアール セラピューティクス インコーポレイテッド | 選択的Ｘａ因子阻害剤 |
| AU6896398A (en) | 1997-04-14 | 1998-11-11 | Cor Therapeutics, Inc. | Selective factor xa inhibitors |
| WO1998046628A1 (en) | 1997-04-14 | 1998-10-22 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
| WO1998054164A1 (en) | 1997-05-30 | 1998-12-03 | Takeda Chemical Industries, Ltd. | Sulfonamide derivatives, their production and use |
| GB9715895D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
| GB9715894D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic derivatives |
| GB9715892D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
| US6525042B1 (en) | 1997-09-30 | 2003-02-25 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
| WO1999033805A1 (fr) * | 1997-12-26 | 1999-07-08 | Mochida Pharmaceutical Co., Ltd. | Composes aromatiques presentant des groupements amino cycliques ou leur sels |
| CN1290254A (zh) | 1998-02-05 | 2001-04-04 | 武田药品工业株式会社 | 氨磺酰衍生物及其制备和用途 |
| JP2000204081A (ja) * | 1998-02-05 | 2000-07-25 | Takeda Chem Ind Ltd | スルホンアミド誘導体、その製造法及び用途 |
| WO1999046267A1 (en) * | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| DE19835950A1 (de) * | 1998-08-08 | 2000-02-10 | Merck Patent Gmbh | Piperazinonderivate |
-
1999
- 1999-01-27 CN CN99803501A patent/CN1291892A/zh active Pending
- 1999-01-27 DE DE69934093T patent/DE69934093T2/de not_active Expired - Lifetime
- 1999-01-27 AU AU26533/99A patent/AU745425B2/en not_active Ceased
- 1999-01-27 TR TR2000/02182T patent/TR200002182T2/xx unknown
- 1999-01-27 UA UA2000085034A patent/UA59433C2/uk unknown
- 1999-01-27 BR BR9907300-5A patent/BR9907300A/pt not_active IP Right Cessation
- 1999-01-27 IL IL13751799A patent/IL137517A0/xx active IP Right Grant
- 1999-01-27 PL PL99342243A patent/PL342243A1/xx not_active Application Discontinuation
- 1999-01-27 CA CA2319198A patent/CA2319198C/en not_active Expired - Fee Related
- 1999-01-27 AT AT99906684T patent/ATE346050T1/de not_active IP Right Cessation
- 1999-01-27 YU YU47600A patent/YU47600A/sh unknown
- 1999-01-27 HU HU0101810A patent/HUP0101810A3/hu unknown
- 1999-01-27 SK SK1108-2000A patent/SK11082000A3/sk unknown
- 1999-01-27 KR KR1020007008221A patent/KR20010034442A/ko not_active Application Discontinuation
- 1999-01-27 EA EA200000768A patent/EA200000768A1/ru unknown
- 1999-01-27 AP APAP/P/2000/001889A patent/AP2000001889A0/en unknown
- 1999-01-27 WO PCT/US1999/001682 patent/WO1999037304A1/en active IP Right Grant
- 1999-01-27 EE EEP200000435A patent/EE200000435A/xx unknown
- 1999-01-27 EP EP99906684A patent/EP1051176B1/en not_active Expired - Lifetime
- 1999-01-27 JP JP2000528286A patent/JP4676613B2/ja not_active Expired - Fee Related
- 1999-01-27 ZA ZA9900607A patent/ZA99607B/xx unknown
-
2000
- 2000-07-25 IL IL137517A patent/IL137517A/en not_active IP Right Cessation
- 2000-07-25 BG BG104633A patent/BG104633A/bg unknown
- 2000-07-25 NO NO20003808A patent/NO20003808L/no not_active Application Discontinuation
- 2000-07-25 IS IS5574A patent/IS5574A/is unknown
-
2003
- 2003-07-25 US US10/628,093 patent/US7612075B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69934093T2 (de) | 2007-06-21 |
| EE200000435A (et) | 2002-02-15 |
| EA200000768A1 (ru) | 2001-06-25 |
| EP1051176A4 (en) | 2002-06-12 |
| NO20003808L (no) | 2000-09-26 |
| BG104633A (bg) | 2001-03-30 |
| TR200002182T2 (tr) | 2000-12-21 |
| WO1999037304A1 (en) | 1999-07-29 |
| CA2319198C (en) | 2011-02-22 |
| AP2000001889A0 (en) | 2000-09-30 |
| CA2319198A1 (en) | 1999-07-29 |
| HUP0101810A2 (hu) | 2002-04-29 |
| NO20003808D0 (no) | 2000-07-25 |
| UA59433C2 (uk) | 2003-09-15 |
| SK11082000A3 (sk) | 2001-01-18 |
| AU745425B2 (en) | 2002-03-21 |
| YU47600A (sh) | 2002-09-19 |
| ATE346050T1 (de) | 2006-12-15 |
| PL342243A1 (en) | 2001-06-04 |
| IL137517A (en) | 2006-12-10 |
| US20040102450A1 (en) | 2004-05-27 |
| IL137517A0 (en) | 2001-07-24 |
| KR20010034442A (ko) | 2001-04-25 |
| HUP0101810A3 (en) | 2002-05-28 |
| BR9907300A (pt) | 2000-10-24 |
| JP2002501024A (ja) | 2002-01-15 |
| DE69934093D1 (de) | 2007-01-04 |
| IS5574A (is) | 2000-07-25 |
| US7612075B2 (en) | 2009-11-03 |
| AU2653399A (en) | 1999-08-09 |
| EP1051176B1 (en) | 2006-11-22 |
| EP1051176A1 (en) | 2000-11-15 |
| JP4676613B2 (ja) | 2011-04-27 |
| CN1291892A (zh) | 2001-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA99607B (en) | Substituted oxoazaheterocyclyl factor xa inhibitors. | |
| ZA200306490B (en) | Inhibitors of factor Xa. | |
| HK1040253A1 (en) | Factor viia inhibitors. | |
| EP1140871A4 (en) | THROMBIN OR FACTOR XA INHIBITORS | |
| ZA996185B (en) | Sulfanylsilanes. | |
| ZA200005136B (en) | Dihydropyrimides. | |
| ZA200201829B (en) | New phenylpiperazines. | |
| ZA996133B (en) | Substituted benzamides. | |
| ZA991272B (en) | Novel thiobenzamides. | |
| ZA200108968B (en) | New compounds. | |
| GB0017742D0 (en) | New case | |
| ZA992443B (en) | Hydroxy-methyl-hexanones. | |
| ZA200110053B (en) | Factor via inhibitors. | |
| PL350941A1 (en) | Pyrazole-3-on-derivative as factor xa inhibitors | |
| ZA200007405B (en) | Angiogenesis inhibitors. | |
| ZA993123B (en) | Trisresorcinyltriazines. | |
| ZA995325B (en) | Methylcyclotetradec-5-en-1-ones. | |
| ZA992899B (en) | Novel compound. | |
| GB9816729D0 (en) | Substituted cyclohexylaminopyrimidines | |
| HK1039937A1 (zh) | 取代的3-硫代氨基甲酰基吡唑類化合物 | |
| PL347397A1 (en) | Substituted 3-aryl-pyrazoles | |
| HUP0102476A3 (en) | Substituted cyclooctadepsipeptides | |
| HK1039335A1 (zh) | 取代的苯甲酰基環已二酮類化合物 | |
| ZA992106B (en) | Statin-MMP inhibitor combinations. | |
| GB0005589D0 (en) | New |